Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma
Along with previously published safety data, EV+P demonstrated benefit compared with chemotherapy across all prespecified subgroups, consistent with the ITT population and supporting EV+P as the standard of care for first-line treatment of la/mUC.
Authors
- D Castellano
- Eiji Kikuchi (ORCID: https://orcid.org/0000-0002-1624-6676)
- Christof Vulsteke (ORCID: https://orcid.org/0000-0002-4607-5660)
- Nataliya Mar (ORCID: https://orcid.org/0000-0003-2485-6201)
- Waddah Arafat (ORCID: https://orcid.org/0000-0002-6057-2348)
- Y. Loriot
- S.S. Sridhar
- Michiel S. van der Heijden (ORCID: https://orcid.org/0000-0002-4407-7881)
- Umang Swami (ORCID: https://orcid.org/0000-0003-3518-0411)
- Jean Hoffman‐Censits (ORCID: https://orcid.org/0000-0002-6970-6509)
- Yingdong Lu (ORCID: https://orcid.org/0000-0003-4369-4084)
- Begoña P. Valderrama (ORCID: https://orcid.org/0000-0003-0175-1263)
- Alexandra Drakaki (ORCID: https://orcid.org/0000-0001-8865-3548)
- Gopa Iyer (ORCID: https://orcid.org/0000-0002-5093-6099)
- Matt D. Galsky
- Seema Rao Gorla (ORCID: https://orcid.org/0009-0006-5256-2189)
- J.P. Maroto Rey
- Jens Bedke (ORCID: https://orcid.org/0000-0003-2778-3108)
- Blanca Homet Moreno (ORCID: https://orcid.org/0000-0001-6712-8330)
- I. Durán (ORCID: https://orcid.org/0000-0002-7396-5407)
- Evan Y. Yu (ORCID: https://orcid.org/0000-0002-1510-8044)
- Xuesong Yu (ORCID: https://orcid.org/0000-0003-1114-9495)
- Thomas Powles
- Shilpa Gupta (ORCID: https://orcid.org/0000-0001-6494-5853)
- Nancy A. Dawson
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Cleveland Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of California, Los Angeles (US)
- St. Marianna University School of Medicine (JP)
- Queen Mary University of London (GB)
- Pfizer (United States) (US)
- Georgetown University (US)
- University of Toronto (CA)
- University of California, Irvine (US)
- University of Utah (US)
- Huntsman Cancer Institute (US)
- Hospital de Sant Pau (ES)
- Institut Gustave Roussy (FR)
- Princess Margaret Cancer Centre (CA)
- Fred Hutch Cancer Center (US)
- University of California, Irvine Medical Center (US)
- Hospital Universitario 12 De Octubre (ES)
- Oncode Institute (NL)
- Instituto de Investigación Marqués de Valdecilla (ES)
- UC Irvine Health (US)
- AZ Maria Middelares (BE)
- Hospital Universitario Virgen del Rocío (ES)
- Klinikum Stuttgart (DE)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Astellas Pharma (United States) (US)
- Georgetown Lombardi Comprehensive Cancer Center
- The University of Texas Southwestern Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105544
- Citations
- 5
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 10.03
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Merck KGaA
- Exelixis
- Clovis Oncology
- Accuray
- Mirati Therapeutics
- Incyte
- G1 Therapeutics
- Seagen
- Daiichi-Sankyo
- Eisai
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders
- Ipsen
- EUSA Pharma
- Genentech